Leflunomide

• Description :

  Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

• CAS Number :

  [75706-12-6]

• Product Name Alternative :

  HWA486; RS-34821; SU101

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H315, H319, H335

• Target :

  Bacterial; Dihydroorotate Dehydrogenase; Endogenous Metabolite

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/leflunomide.html

• Purity :

  99.82

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  O=C(C1=C(C)ON=C1)NC2=CC=C(C(F)(F)F)C=C2

• Molecular Formula :

  C12H9F3N2O2

• Molecular Weight :

  270.21

• Precautions :

  H301, H315, H319, H335

• References & Citations :

  [1]Davis JP, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35 (4) :1270-3.|[2]Xu X, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995 May 26;270 (21) :12398-403.|[3]Fox RI, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93 (3) :198-208.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched